

CURRICULUM VITAE

Name: Celso Arango, M.D., Ph.D.
Institution: Child and Adolescent Department of Psychiatry at Hospital General Universitario Gregorio Marañón
Address: Ibiza, 43. 28009 Madrid. Spain
Telephone number: +34- 914265006
E-mail: carango@hggm.es
Fax: +34- 914265005

EDUCATION

1992 Degree in Medicine and Surgery. University of Oviedo, Spain.
1986-1990 Faculty of Medicine. University of Oviedo.
1991-1992 Medicine School. Manchester University (U.K.), sponsored by ERASMUS program.
1997 Psychiatry specialist. Education and Culture Department. Gregorio Marañón General University Hospital. Madrid, Spain.
1997 Doctor in Medicine (Ph.D.). University Complutense of Madrid, Spain. Doctoral thesis: "Insight and violence in schizophrenia".

PROFESSIONAL EXPERIENCE

1/93 to 12/96 Residency in psychiatry. Gregorio Marañón General University Hospital. Madrid. Spain
1/97 to 2/99 Maryland Psychiatric Research Center. (School of Medicine, University of Maryland. U.S.A.). *Research Fellow*.
6/99 to 2/09 Department of Psychiatry. Gregorio Marañón General University Hospital. Research Department. University Complutense, Madrid, Spain. *Assistant Professor of Psychiatry*.
2/09 to Present Department of Psychiatry. Gregorio Marañón General University Hospital. Research Department. University Complutense, Madrid, Spain. *Associate Professor of Psychiatry*.
6/99 to 3/12 Department of Psychiatry. Gregorio Marañón General University Hospital. Madrid, Spain. *Head of Psychiatric Adolescent Unit*
3/12 to Present Department of Child and Adolescent Psychiatry. Hospital General Universitario Gregorio Marañón. Madrid, Spain. *Head of Department*.
2/99 to 5/05 School of Medicine, Maryland Psychiatric Research Center. University of Maryland USA. *Volunteer Research Assistant Professor of Psychiatry*.
5/05 to 6/13 School of Medicine, Maryland Psychiatric Research Center. University of Maryland USA. *Volunteer Associate Professor of Psychiatry*.
1/08 to Present *Scientific Director. Spanish Mental Health Network (CIBERSAM). Ministry of Economy and Competitiveness*.
6/13 to Present School of Medicine, Maryland Psychiatric Research Center. University of Maryland USA. *Adjunct Professor of Psychiatry*.

RESEARCH PROJECTS

Dr. Arango has participated in more than 68 competitively funded research projects being Principal investigator in 50 of them. The research projects have been funded by the Spanish Ministry of Health, Spanish Ministry of Science and Innovation, NIMH, NARSAD, Stanley Foundation, Fundación Alicia Koplowitz, Caja Navarra, Department of Health in the State of Madrid and he currently participates in eight EU projects funded by the VII Framework. He has been coordinator of the Spanish Network in Early Onset Psychosis and the Mental Disease - Affective disorders and Psychosis Research Network funded by the Ministry of Health.

He is now Scientific Director of the Spanish Centre for Biomedical Research in Mental Health (CIBERSAM, www.cibersam.es). The CIBERSAM is composed of 25 clinical and basic research groups belonging to 8 Autonomous Communities, which primarily research mental disorders such as depression, schizophrenia, and bipolar disorder, as well as anxiety disorders, child and adolescent diseases, geriatric diseases and, in general, any neuroscientific aspect related to health and mental illness. The approach to studying these diseases has a clear translational component, seeking synergy among groups that perform their work in hospitals, research centres, and universities. The CIBERSAM comprises a human team of about 400 researchers, with a staff of more than 120 professionals hired by the Centre, the rest being members of personnel groups attached to the CIBERSAM.

SELECTED SCIENTIFIC PAPERS (I.F.: Impact Factor ISI 2012)

Arango, C.; Carpenter, W.T. Jr.; Queern, C.A. Research Ethics: A psychological approach. *Clinical Psychology Review*, 19(3): 384-5, 1999. (I.F.: 6.696).

Arango, C.; Adami, H.; Sherr, J.D.; Thacker, G.; Carpenter, W.T. Jr. Relationship of awareness of dyskinesia in schizophrenia to insight into mental illness. *American Journal of Psychiatry*, 156(7): 1097-99, 1999. (I.F.: 14.721).

Carpenter, W.T. Jr.; Arango, C.; Buchanan, R.W.; Kirkpatrick, B. Deficit psychopathology and a paradigm shift in schizophrenia research. *Biological Psychiatry*, 46: 352-60, 1999. (I.F.: 9.247).

Arango, C.; Bartko, J.J.; Gold, J.M.; Buchanan, R.W. Prediction of neuropsychological performance by neurological signs in schizophrenia. *American Journal of Psychiatry*, 156(9): 1358-66, 1999. (I.F.: 14.721).

Arango, C.; Calcedo, A. Jr.; Gonzalez-Salvador, T.; Calcedo, A. Violence in inpatients with schizophrenia: a prospective study. *Schizophrenia Bulletin*, 25(3): 493-503, 1999. (I.F.: 8.486).

Arango, C.; Kirkpatrick, B.; Buchanan, R.W. Neurological signs and the heterogeneity of schizophrenia. *American Journal of Psychiatry*, 157(4): 560-5, 2000. (I.F.: 14.721).

Arango, C.; Kirkpatrick, B.; Koenig, J.I. At issue: stress, hippocampal neuronal turnover and neuropsychiatric disorders. *Schizophrenia Bulletin*, 27(3): 477-80, 2001. (I.F.: 8.486).

Arango, C.; Rojas, M.J.; Moreno, D.; Parellada, M. Sibutramine for compulsive eating in hypothalamic deficiency. *Journal of the American Academy of Child and Adolescent Psychiatry*, 41(10):1147-8, 2002. (I.F.: 6.970).

Bobes, J.; García-Portilla, M.P.; Sáiz, P.A.; Bascarán, M.T.; Bousoño, M.; Arango, C. High degree of tolerability for monotherapy with high doses of quetiapine: a case report. *Journal of Clinical Psychiatry*, 63: 1048-9, 2002. (I.F.: 5.812).

Arango, C.; Breier, A.; MacMahon, R.; Carpenter, W.T.; Buchanan, R.W. The relationship of clozapine and haloperidol treatment to prefrontal, hippocampal and caudate brain volumes. *American Journal of Psychiatry*, 160(8): 1421-7, 2003. (I.F.: 14.721).

Arango, C.; Summerfelt, A.; Buchanan, R.W. Olanzapine effects on auditory sensory gating in schizophrenia. *American Journal of Psychiatry*, 160(11): 2066-8, 2003. (I.F.: 14.721).

- Buchanan, R.W.; Francis, A.; Arango, C.; Miller, K.; Lefkowitz, D.M.; McMahon, R.P.; Barta, P.E.; Pearlson, G.D. Morphometric assessment of the heteromodal cortex in schizophrenia. *American Journal of Psychiatry*, 161(2): 322-31, 2004. (I.F.: 14.721).
- Bombín, I.; Arango, C.; Buchanan, R.W. Significance and meaning of neurological signs in schizophrenia: Two Decades Later. *Schizophrenia Bulletin*, 31(4): 962-77, 2005. (I.F.: 8.486).
- Moreno, MD.; Burdalo M.; Reig, S.; Parellada, M.; Zabala, A.; Desco, M.; Baca-Baldomero, E.; Arango, C. Structural neuroimaging in adolescents with a first psychotic episode. *Journal of the American Academy of Child and Adolescent Psychiatry*, 44(11): 1151-1157, 2005. (I.F.: 6.970).
- van Os, J.; Burns, T.; Cavallaro, R.; Leucht, S.; Peuskens, J.; Helldin, L.; Bernardo, M.; Arango, C.; Fleischhacker, W.; Lachaux, B.; Kane, J.M. Standardized remission criteria in schizophrenia. *Acta Psychiatrica Scandinavica*, 113(2): 91-5, 2006. (I.F.: 4.857).
- Artaloytia, J.F.; Arango, C.; Lahti, A.; Sanz, J.; Pascual, A.; Cubero, P.; Prieto, D.; Palomo, T. Negative signs and symptoms secondary to antipsychotics: A double-blind randomized trial of single dose of placebo, haloperidol and risperidone in healthy volunteers. *American Journal of Psychiatry*, 163(3): 488-93, 2006. (I.F.: 14.721).
- Soto-Montenegro, M.L.; Vaquero, J.J.; Arango, C.; Ricaurte, G.; Garcia-Barreno, P.; Desco, M. Effects of MDMA administration on blood glucose levels and brain glucose metabolism. *European Journal of Nuclear Medicine and Molecular Imaging*, 34(6):916-25, 2007. (I.F.: 5.114).
- Robles, O.; Blaxton, T.; Adami, H.; Arango, C.; Thaker, G.; Gold, J. Nonverbal delayed recognition in the relatives of schizophrenia patients with or without schizophrenia spectrum. *Biological Psychiatry*, 63(5):498-504, 2008. (I.F.: 9.247).
- Arango, C.; Moreno, C.; Martínez, S.; Parellada, M.; Desco, M.; Moreno, D.; Fraguas, D.; Gogtay, N.; James, A.; Rapoport, J. Longitudinal Brain Changes in Early-Onset Psychosis. *Schizophrenia Bulletin*, 34(2):341-53, 2008. (I.F.: 8.486).
- Arango, C.; Kahn, R. Progressive Brain Changes in Schizophrenia. *Schizophrenia Bulletin*, 34(2):310-1, 2008. (I.F.: 8.486).
- Fraguas, D.; Merchán-Naranjo, J.; Laita, P.; Parellada, M.; Moreno, D.; Ruiz-Sancho, A.; Cifuentes, A.; Giráldez, M.; Arango, C. Metabolic and hormonal side effects in children and adolescents treated with second generation antipsychotics. *Journal of Clinical Psychiatry*, 69(7):1166-75, 2008. (I.F.: 5.812).
- Rosa, AR.; Franco, C.; Martínez-Aran, A.; Sánchez-Moreno, J.; Reinares, M.; Salamero, M.; Arango, C.; Ayuso-Mateos, J.L.; Kapczinski, F.; Vieta, E. Functional impairment in patients with remitted bipolar disorder. *Psychotherapy and Psychosomatics*, 77(6):390-392, 2008. (I.F.: 7.230).
- Janssen, J.; Reig, S.; Parellada, M.; Moreno, MD.; Graell, M.; Fraguas, D.; Zabala, A.; García-Vazquez, V.; Desco, M.; Arango, C. Regional gray matter volume deficits in adolescents with first-episode psychosis. *Journal of the American Academy of Child and Adolescent Psychiatry*, 47(11):1311-20, 2008. (I.F.: 6.970).
- Parellada, M.; Fraguas, D.; Bombín, I.; Otero, S.; Castro-Fornieles, J.; Baeza, I.; Gonzalez-Pinto, A.; Graell, M.; Soutullo, C.; Payá, B.; Arango, C. Insight correlates in child- and adolescent-onset first episodes of psychosis: results from the CAFEPS study. *Psychological Medicine*, 39(9):1433-45, 2009. (I.F.: 5.587).
- Reig, S.; Moreno, C.; Moreno, D.; Burdalo, M.; Janssen, J.; Parellada, M.; Zabala, A.; Desco, M.; Arango, C. Progression of Brain Volume Changes in Adolescent-Onset Psychosis. *Schizophrenia Bulletin*, 35(1):233-43, 2009. (I.F.: 8.486).
- Reig, S.; Sánchez, J.; Arango, C.; Castro, J.; González-Pinto, A.; Ortuño, F.; Crespo-Facorro, B.; Bargalló, N.; Desco, M. Assessment of the increase in variability when combining volumetric data from different scanners. *Human Brain Mapping*, 30(2):355-368, 2009. (I.F.: 6.878).
- Balanzá-Martínez, V.; Cuesta, MJ.; Arango, C.; Crespo-Facorro, B.; Tabarés-Seisdedos, R. Longitudinal course of cognition in schizophrenia. *British Journal of Psychiatry*, 195(1):84, 2009. (I.F.: 6.606).

Stefansson, H.; Ophoff, RA.; Steinberg, S.; Andreassen, OA.; Cichon, S.; Rujescu, D.; Werge, T.; Pietiläinen, OP.; Mors, O.; Mortensen, PB.; Sigurdsson, E.; Gustafsson, O.; Nyegaard, M.; Tuulio-Henriksson, A.; Ingason, A.; Hansen, T.; Suvisaari, J.; Lonnqvist, J.; Paunio, T.; Børglum, AD.; Hartmann, A.; Fink-Jensen, A.; Nordentoft, M.; Hougaard, D.; Norgaard-Pedersen, B.; Böttcher, Y.; Olesen, J.; Breuer, R.; Möller, HJ.; Giegling, I.; Rasmussen, HB.; Timm, S.; Mattheisen, M.; Bitter, I.; Réthelyi, JM.; Magnusdottir, BB.; Sigmundsson, T.; Olason, P.; Masson, G.; Gulcher, JR.; Haraldsson, M.; Fossdal, R.; Thorgeirsson, TE.; Thorsteinsdottir, U.; Ruggeri, M.; Tosato, S.; Franke, B.; Strengman, E.; Kiemene, LA.; Genetic Risk and Outcome in Psychosis (GROUP); Melle, I.; Djurovic, S.; Abramova, L.; Kaleda, V.; Sanjuan, J.; de Frutos, R.; Bramon, E.; Vassos, E.; Fraser, G.; Ettinger, U.; Picchioni, M.; Walker, N.; Touloupoulou, T.; Need, AC.; Ge, D.; Yoon, JL.; Shianna, KV.; Freimer, NB.; Cantor, RM.; Murray, R.; Kong, A.; Golimbet, V.; Carracedo, A.; Arango, C.; Costas, J.; Jönsson, EG.; Terenius, L.; Agartz, I.; Petursson, H.; Nöthen, MM.; Rietschel, M.; Matthews, PM.; Muglia, P.; Peltonen, L.; St Clair, D.; Goldstein, DB.; Stefansson, K.; Collier, DA. Common variants conferring risk of schizophrenia. *Nature*, 460(7256):744-7, 2009. (I.F.: 38.597).

Janssen, J.; Diaz-Caneja, A.; Reig, S.; Bombín, I.; Mayoral, M.; Parellada, M.; Graell, M.; Moreno, D.; Zabala, A.; García-Vazquez, V.; Desco, M.; Arango, C. Brain morphology and neurological soft signs in adolescents with first-episode psychosis. *British Journal of Psychiatry*, 195(3):227-33, 2009. (I.F.: 6.606).

Janssen, J.; Reig, S.; Aleman, Y.; Schnack, H.; Udias, JM.; Parellada, M.; Graell, M.; Moreno, D.; Zabala, A.; Balaban, E.; Desco, M.; Arango, C. Gyrus and sulcal cortical thinning in adolescents with first episode early-onset psychosis. *Biological Psychiatry*, 66(11):1047-54, 2009. (I.F.: 9.247).

Rapado-Castro, M.; Soutullo, C.; Fraguas, D.; Arango, C.; Payá, B.; Castro-Fornieles, J.; González-Pinto, A.; Parellada, M.; Graell, M.; Baeza, I.; Bombin, I. Predominance of symptoms over time in early-onset psychosis: a principal component factor analysis of the Positive and Negative Syndrome Scale. *Journal of Clinical Psychiatry*, 71(3):327-37, 2010. (I.F.: 5.799).

Bobes, J.; Arango, C.; Rejas, J.; for the CLAMORS Study Collaborative Group. Prevalence of negative symptoms in outpatients with schizophrenia spectrum disorders treated with antipsychotics in routine clinical practice: findings from the CLAMORS Study. *Journal of Clinical Psychiatry*, 71(3):280-6, 2010. (I.F.: 5.812).

Arango, C.; Amador, X. Lessons learned about poor insight. *Schizophrenia Bulletin*, 37(1):27-8, 2011. (I.F.: 8.486).

Parellada, M.; Boada, L.; Fraguas, D.; Reig, S.; Castro-Fornieles, J.; Moreno, D.; Gonzalez-Pinto, A.; Otero, S.; Rapado-Castro, M.; Graell, M.; Baeza, I.; Arango, C. Trait and state attributes of insight in first Episodes of early-onset schizophrenia and other psychoses: A 2-year longitudinal study. *Schizophrenia Bulletin*, 37(1):38-51, 2011. (I.F.: 8.486).

Ayuso-Mateos, JL.; Wykes, T.; Arango, C. The Madrid Declaration: why we need a coordinated European-wide effort in mental health research. *British Journal of Psychiatry*, 198:253-5, 2011. (I.F.: 6.606).

Robles, O.; Zabala, A.; Bombín, I.; Parellada, M.; Moreno, D.; Ruiz-Sancho, A.; Arango, C. Cognitive Efficacy of Quetiapine and Olanzapine in Early-Onset First-Episode Psychosis. *Schizophrenia Bulletin*, 37(2):405-15, 2011. (I.F.: 8.486).

González-Pinto, A.; Alberich, S.; Barbeito, S.; Gutierrez, M.; Vega, P.; Ibáñez, B.; Haidar, MK.; Vieta, E.; Arango, C. Cannabis and first-episode psychosis: Different long-term outcomes depending on continued or discontinued use. *Schizophrenia Bulletin*, 37(3):631-9, 2011. (I.F.: 8.486).

Desco, M.; Navas-Sanchez, FJ.; Sanchez-González, J.; Reig, S.; Robles, O.; Franco, C.; Guzmán-De-Villoria, J.; García-Barreno, P.; Arango, C. Mathematically gifted adolescents use more extensive and more bilateral areas of the fronto-parietal network than controls during executive functioning and fluid reasoning tasks. *Neuroimage*, 57(1): 281-92, 2011. (I.F.: 6.252).

Castro-Fornieles, J.; Baeza, I.; de la Serna, E.; Gonzalez-Pinto, A.; Parellada, M.; Graell, M.; Moreno, D.; Otero, S.; Arango, C. Two-year diagnostic stability in early-onset first-episode psychosis. *Journal of Child Psychology and Psychiatry*, 52(10):1089-98, 2011. (I.F.: 5.422).

Steinberg, S.; de Jong, S.; Irish Schizophrenia Genomics Consortium ; Andreassen, OA.; Werge, T.; Børglum, AD.; Mors, O.; Mortensen, PB.; Gustafsson, O.; Costas, J.; Pietiläinen, OP.; Demontis, D.; Papiol, S.; Huttenlocher, J.; Mattheisen, M.; Breuer, R.; Vassos, E.; Giegling, I.; Fraser, G.; Walker, N.; Tuulio-Henriksson, A.; Suvisaari, J.;

Lönnqvist, J.; Paunio, T.; Agartz, I.; Melle, I.; Djurovic, S.; Strengman, E; GROUP; Jürgens, G.; Glenthøj, B.; Terenius, L.; Hougaard, DM.; Orntoft, T.; Wiuf, C.; Didriksen, M.; Hollegaard, MV.; Nordentoft, M.; van Winkel, R.; Kenis, G.; Abramova, L.; Kaleda, V.; Arrojo, M.; Sanjuán, J.; Arango, C.; Sperling, S.; Rossner, M.; Ribolsi, M.; Magni, V.; Siracusano, A.; Christiansen, C.; Kiemeny, LA.; Veldink, J.; van den Berg, L.; Ingason, A.; Muglia, P.; Murray, R.; Nöthen, MM.; Sigurdsson, E.; Petursson, H.; Thorsteinsdottir, U.; Kong, A.; Rubino, IA.; De Hert, M.; Réthelyi, JM.; Bitter, I.; Jönsson, EG.; Golimbet, V.; Carracedo, A.; Ehrenreich, H.; Craddock, N.; Owen, MJ.; O'Donovan, MC; Wellcome Trust Case Control Consortium ; Ruggeri, M.; Tosato, S.; Peltonen, L.; Ophoff, RA.; Collier, DA.; St Clair, D.; Rietschel, M.; Cichon, S.; Stefansson, H.; Rujescu, D.; Stefansson, K. Common Variants at VRK2 and TCF4 Conferring Risk of Schizophrenia. *Human Molecular Genetics*, 20(20):4076-81, 2011. (I.F.: 7.692).

Reig, S.; Parellada, M.; Castro-Fornieles, J.; Janssen, J.; Moreno, D.; Baeza, I.; Bargalló, N.; González-Pinto, A.; Graell, M.; Ortuño, F.; Otero, S.; Arango, C.; Desco, M. Multicenter study of brain volume abnormalities in children and adolescent-onset psychosis. *Schizophrenia Bulletin*, 37(6):1270-80, 2011. (I.F.: 8.486).

Nuevo, R.; Chatterji, S.; Fraguas, D.; Verdes, E.; Naidoo, N.; Arango, C.; Ayuso-Mateos, JL. Increased risk of diabetes mellitus among persons with psychotic symptoms: results from the WHO World Health Survey. *Journal of Clinical Psychiatry*, 72(12):1592-9, 2011. (I.F.: 5.812).

Arango, C.; Rapado Castro, M.; Reig, S.; Castro-Fornieles, J.; González-Pinto, A.; Otero Cuesta, S.; Baeza, I.; Moreno, C.; Graell, M.; Janssen, J.; Parellada, M.; Moreno, D.; Bargalló, N.; Desco, M. Progressive brain changes in children and adolescents with first-episode psychosis. *Archives of General Psychiatry*, 69(1):16-26, 2012. (I.F.: 13.772).

Janssen, J.; Aleman, Y.; Reig, S.; Schnack, H.; Parellada, M.; Graell, M.; Moreno, C.; Moreno, MD.; Mateos-Pérez, JM.; Udias, JM.; Arango, C.; Desco, M. Regional specificity of thalamic volume deficits in male adolescents with early-onset psychosis. *British Journal of Psychiatry*, 200: 30-6, 2012. (I.F.: 6.606).

Mayoral, M.; Bombin, I.; Castro-Fornieles, J.; González-Pinto, A.; Otero, S.; Parellada, M.; Moreno, D.; Baeza, I.; Graell, M.; Rapado, M.; Arango, C. Longitudinal study of neurological soft signs in first-episode early-onset psychosis. *Journal of Child Psychology and Psychiatry*, 53(3):323-31, 2012. (I.F.: 5.422).

Nuevo, R.; Chatterji, S.; Verdes, E.; Naidoo, N.; Arango, C.; Ayuso-Mateos, JL. The Continuum of Psychotic Symptoms in the General Population: A Cross-national Study. *Schizophrenia Bulletin*, 38(3):475-85, 2012. (I.F.: 8.486).

Mac-Dowell, KS.; García-Bueno, B.; Madrigal, JLM.; Parellada, M.; Arango, C.; Micó, JA.; Leza, JC. Risperidone normalizes increased inflammatory parameters and restores anti-inflammatory pathways in a model of neuroinflammation. *International Journal of Neuropsychopharmacology*, 16(1):121-35, 2013. (I.F.: 5.641).

Bombin, I., Mayoral, M., Castro-Fornieles, J., Gonzalez-Pinto, A., de la Serna, E., Rapado-Castro, M., Barbeito, S., Parellada, M., Baeza, I., Graell, M., Payá, B., Arango, C. Neuropsychological evidence for abnormal neurodevelopment associated with early onset psychoses. *Psychological Medicine*, 43(4):757-68, 2013. (I.F.: 5.587).

Sanchez-Gistau, V.; Baeza, I.; Arango, C.; González-Pinto, A.; de la Serna, E.; Parellada, M.; Graell, M.; Paya, B.; Llorente, C.; Castro-Fornieles, J. Predictors of suicide attempt in early-onset, first-episode psychoses: a longitudinal 24-month follow-up study. *Journal of Clinical Psychiatry*, 74(1):59-66, 2013. (I.F.: 5.812).

Arango, C. Child neuropsychopharmacology: good news... the glass is half full. *World Psychiatry*, 12(2):128-9, 2013. (I.F.: 8.974).

Torrent, C.; del Mar Bonnin, C.; Martínez-Arán, A.; del Valle, J.; Amann, B.; González-Pinto, A.; Crespo, JM; Ibañez, A.; García-Portilla, MP.; Tabarés-Seisdedos, R.; Arango, C.; Colom, F.; Solé B.; Pacchiarotti, I.; Rosa, AR.; Ayuso-Mateos, JL; Anaya, C; Fernández, P.; Landín-Romero, R; Alonso, S.; Ortiz-Gil, A.; Segura, B.; Barbeito, S.; Vega, S.; Fernández, S.; Ugarte, A.; Subirà, A.; Cerrillo, E.; Custal, N.; Menchón, JM.; Saiz-Ruiz, J.; Rodao, MJ.; Isella, S.; Alegría, A.; Al-Halabi, S.; Bobes, J.; Galván, G.; Saiz, PA.; Balanzá-Martínez, V.; Selva, G.; Fuentes-Durá, I.; Correa, P.; Mayoral, M.; Chiclana, G.; Merchan-Naranjo, J., Rapado-Castro, M.; Salamero, M.; Vieta, E. Efficacy of Functional Remediation in Bipolar Disorder: A Multicentre, Randomized-Controlled Study. *American Journal of Psychiatry*, 170(8):852-9, 2013. (I.F.: 14.721).

Moreno, C.; Nuevo, R.; Chatterji, S.; Verdes, E.; Arango, C.; Ayuso-Mateos, JL. Psychotic symptoms are associated with physical health problems independently of a mental disorder diagnosis: results from the WHO World Health Survey. *World Psychiatry*, 12(3):251-257, 2013. (I.F.: 8.974).

Alemán-Gómez, Y.; Janssen, J.; Schnack, H.; Balaban, E.; Pina-Camacho, L.; Alfaro-Almagro, F.; Castro-Fornieles, J.; Otero, S.; Baeza, I.; Moreno, D.; Bargalló, N.; Parellada, M.; Arango, C.; Desco, M. The Human Cerebral Cortex Flattens during Adolescence. *Journal of Neuroscience*, 33(38):15004-15010, 2013. (I.F.: 6.908).

Steinberg, S.; de Jong, S.; Mattheisen, M.; Costas, J.; Demontis, D.; Jamain, S.; Pietiläinen, OP.; Lin, K.; Papiol, S.; Huttenlocher, J.; Sigurdsson, E.; Vassos, E.; Giegling, I.; Breuer, R.; Fraser, G.; Walker, N.; Melle, I.; Djurovic, S.; Agartz, I.; Tuulio-Henriksson, A.; Suvisaari, J.; Lönngqvist, J.; Paunio, T.; Olsen, L.; Hansen, T.; Ingason, A.; Pirinen, M.; Strengman, E.; Hougaard, DM.; Orntoft, T.; Didriksen, M.; Hollegaard, MV.; Nordentoft, M.; Abramova, L.; Kaleda, V.; Arrojo, M.; Sanjuán, J.; Arango, C.; Etain, B.; Bellivier, F.; Méary, A.; Schürhoff, F.; Szoke, A.; Ribolsi, M.; Magni, V.; Siracusano, A.; Sperling, S.; Rossner, M.; Christiansen, C.; Kiemeny, LA.; Franke, B.; van den Berg, LH.; Veldink, J.; Curran, S.; Bolton, P.; Poot, M.; Staal, W.; Rehnstrom, K.; Kilpinen, H.; Freitag, CM.; Meyer, J.; Magnusson, P.; Saemundsen, E.; Martsenkovsky, I.; Bikshaieva, I.; Martsenkovska, I.; Vashchenko, O.; Raleva, M.; Paketchieva, K.; Stefanovski, B.; Durmishi, N.; Pejovic Milovancevic, M.; Lecic Tosevski, D.; Silagadze, T.; Naneishvili, N.; Mikeladze, N.; Surguladze, S.; Vincent, JB.; Farmer, A.; Mitchell, PB.; Wright, A.; Schofield, PR.; Fullerton, JM.; Montgomery, GW.; Martin, NG.; Rubino, IA.; van Winkel, R.; Kenis, G.; De Hert, M.; Réthelyi, JM.; Bitter, I.; Terenius, L.; Jönsson, EG.; Bakker, S.; van Os, J.; Jablensky, A.; Leboyer, M.; Bramon, E.; Powell, J.; Murray, R.; Corvin, A.; Gill, M.; Morris, D.; O'Neill, FA.; Kendler, K.; Riley, B.; Wellcome Trust Case Control Consortium 2.; Craddock, N.; Owen, MJ.; O'Donovan, MC.; Thorsteinsdottir, U.; Kong, A.; Ehrenreich, H.; Carracedo, A.; Golimbet, V.; Andreassen, OA.; Børglum, AD.; Mors, O.; Mortensen, PB.; Werge, T.; Ophoff, RA.; Nöthen, MM.; Rietschel, M.; Cichon, S.; Ruggeri, M.; Tosato, S.; Palotie, A.; St Clair, D.; Rujescu, D.; Collier, DA.; Stefansson, H.; Stefansson K. Common variant at 16p11.2 conferring risk of psychosis. *Molecular Psychiatry*, 19(1):108-14, 2014. (I.F.: 14.897).

Díaz-Caneja, CM.; Espliego, A.; Parellada, M.; Arango, C.; Moreno, C. Polypharmacy with antidepressants in children and adolescents. *International Journal of Neuropsychopharmacology*. (In press). (I.F.: 5.641).

Navas-Sánchez, FJ.; Alemán-Gómez, Y.; Sánchez-Gonzalez, J.; Guzmán-De-Villoria, JA.; Franco, C.; Robles, O.; Arango, C.; Desco, M. White matter microstructure correlates of mathematical giftedness and intelligence quotient. *Human Brain Mapping*. (In press). (I.F.: 6.878).

Arango, C.; Fraguas, D.; Parellada, M. Differential neurodevelopmental trajectories in patients with early-onset bipolar and schizophrenia disorders. *Schizophrenia Bulletin*. (In press). (I.F.: 8.486).

COURSES, QUALIFICATONS, AWARDS AND GRANTS

- | | |
|------|---------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------|
| 1998 | Selected for the American Psychiatric Association Research Colloquium for Junior Investigators (Neuroimaging). Toronto, USA. |
| 1999 | The Theodore and Vada Stanley Foundation Award (2 years). Prediction and prevention of violence in outpatient schizophrenia. |
| 2002 | Young Scientist Award. 11th Biennial Winter Workshop on Schizophrenia. Davos, Switzerland. |
| 2004 | Young Travel Award 17 th ECNP (European College of Neuropsychopharmacology) Congress. Poster: <i>Safety and tolerability of antipsychotics in children and adolescents: Preliminary results of a longitudinal study</i> . Stockholm, Sweden. |
| 2006 | Research excellence Award for Key Researchers. Spanish Society of Psychiatry Scientific Paper: <i>Structural Neuroimaging in Adolescent with First Psychotic Episode</i> . October, 2006 |
| 2007 | Poster Award. European Neuropsychopharmacology. Poster: <i>Prefrontal cortex N-acetyl-aspartate in early onset psychosis: cognitive correlates, course and predictive value</i> . 2007. |
| 2010 | Amadeo Sánchez Blanqué Award.: <i>Longitudinal 2 years follow up study on insight in a cohort of child and adolescents with a first psychotic episode</i> . October, 2010. |
| 2011 | CIBERSAM Travel Award. <i>Cognitive evaluation in adolescents with a first psychotic episode and their first degree families</i> . October, 2011. |
| 2013 | Best International Paper Award: <i>Progressive brain changes in children and adolescents with first-episode psychosis</i> . Research Committee. Álava Hospital. Vitoria. January, 2013. |

- 2013 Best Research in Biomedicine 2013 Award. Program for Comprehensive Care of patients with Autism Spectrum Disorders (AMI-TEA). Diario La Razon. Madrid, July, 2013.

CLINICAL MANAGEMENT AWARDS

- 2005 V Comunidad de Madrid Excellence Award (with special honours) to the Adolescents Unit, Psychiatry department, Gregorio Marañón General University Hospital. Madrid, February, 2005.
- 2006 Innovation and Clinical Management Pfizer Award. Pfizer Chair, Madrid. September, 2006.
- 2006 Assistance Centers and Other Entities 1st Award to the Adolescents Unit, Psychiatry department, Gregorio Marañón General University Hospital. Patient Service 2006 Awards. Farmaindustria Foundation, Madrid. December, 2006.
- 2008 VI Comunidad de Madrid Excellence Award. Winner to the quality and excellence in managements of all public facilities within the Community. Adolescents Unit, Psychiatry Department, Gregorio Marañón General University Hospital. Madrid. December, 2008.
- 2009 Clinical Excellence Award from the Psychiatry Spanish Society. Adolescents Unit, Psychiatry Department, Gregorio Marañón General University Hospital. Madrid. October, 2009.
- 2009 "Childhood Awards" to the Adolescents Unit, Psychiatry department, Gregorio Marañón General University Hospital. Madrid, December, 2009 by the Autonomous Community of Madrid.
- 2012 Recognition for Research and Health to the Gregorio Marañón Hospital AMI-TEA team. Autism Federation of Madrid Awards 2012. Madrid. March 2012.
- 2012 Best Spanish Centre Award for Treatment in Schizophrenia. VII Best in Class Awards 2012. Gazeta Médica. Madrid. October, 2012.
- 2012 "Virtual Simulation in Mental health". Best Ideas of Health Award 2012. Diario Médico. Barcelona. November, 2012.
- 2013 Quality Excellence Award: Mental Health and Addiction to Department of Child and Adolescent Psychiatry. Avedis Donabedian Foundation. Madrid. February, 2013.

SCIENTIFIC JOURNALS

Schizophrenia Bulletin (Editorial Board), European Psychiatry (Editorial Board), European Child and Adolescent Psychiatry (Editorial board), European Neuropsychopharmacology (Editorial Board), Spanish Journal of Psychiatry and Mental Health (Co-Editor in Chief), Journal of Child and Adolescent Psychopharmacology (Editorial board), European Archives of Psychiatry and Clinical Neuroscience (Editorial board), Archives of General Psychiatry (reviewer), Schizophrenia Bulletin (reviewer), Biological Psychiatry (reviewer), Psychiatry Research (reviewer), Schizophrenia Research (reviewer), and many others.

OTHERS

- Member of Executive Committee of the European College of Neuropsychopharmacology (ECNP) since October, 2002.
- President of the ECNP Educational Committee from September 2009.
- Secretary Spanish Society of Biological Psychiatry since October 2008.
- Member of the International Advisory Board for the Schizophrenia International Research Society.
- Member of the Executive Committee of the Association of Spanish Psychiatry (SEP) November, 2002-2005.
- Fellow of the Association of European Psychiatry (AEP) since October, 2003.
- President of the Research Commission of Gregorio Marañón General University Hospital, since November, 2003.

- Member of the Neuroimaging Section of the European Association of Psychiatry since 2003.
- Member of the International Committee of the International Neuropsychiatric Association, 2004.
- Assessor of the European Agency for the Evaluation of Medical Products (EMA). Pre-authorization of medicines for human use.
- Assessor of the Spanish Drug Agency (National Health Department).
- Chair of the ECNP Child and Adolescent Neuropsychopharmacology Network since 2005.
- Member of Educational Committee of the European College of Neuropsychopharmacology (ECNP) since March, 2005.
- Member of many Scientific Committees for International Meetings. Co-chair of the Schizophrenia International Research Society, Firenze 2010.
- Member of the Schizophrenia International Research Society Board of Directors since 2012
- Coordinator of the Neuroscience and Mental Health Area of the Gregorio Marañón Research Institute (IISGM) since 2012.
- Board Member of the Gregorio Marañón Research Institute (IISGM) since 2012.
- Member of the Executive Committee of the Gregorio Marañón Research Institute (IISGM) since 2012.
- Member of the Perceived Quality Committee of Hospital General Universitario Gregorio Marañón since 2012.
- Member of the European Brain Council since 2013.
- President-Elect of European College of Neuropsychopharmacology (ECNP) since 2013.
- External referee of the European Research Council Starting Grant 2013 project proposals.
- Fluent written and spoken Spanish, English and Catalan.